These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20736807)

  • 1. Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
    Becker A; van Wijk A; Smit EF; Postmus PE
    J Thorac Oncol; 2010 Sep; 5(9):1477-80. PubMed ID: 20736807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Galetta D; Colantuoni G; Del Gaizo F; Ferrara C; Guerriero C; Nicolella D; Rossi A
    J Thorac Oncol; 2007 Aug; 2(8):758-61. PubMed ID: 17762344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmar bullous blistering induced by erlotinib.
    Berg A; Brustugun OT; Lund-Iversen M; Helland Å
    J Thorac Oncol; 2011 May; 6(5):954. PubMed ID: 21623268
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.
    Lind JS; Postmus PE; Smit EF
    J Thorac Oncol; 2010 Apr; 5(4):554-7. PubMed ID: 20357621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
    Weber B; Sorensen BS; Knap MM; Madsen HH; Nexo E; Meldgaard P
    J Thorac Oncol; 2011 Nov; 6(11):1946-9. PubMed ID: 22005472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
    Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
    Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
    Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
    J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
    [No Abstract]   [Full Text] [Related]  

  • 12. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
    Vasile E; Tibaldi C; Chella A; Falcone A
    J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
    Pennell NA; Yin L; Keshtgarpour M; Ma PC
    J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
    Togashi Y; Masago K; Fukudo M; Terada T; Fujita S; Irisa K; Sakamori Y; Kim YH; Mio T; Inui K; Mishima M
    J Thorac Oncol; 2010 Jul; 5(7):950-5. PubMed ID: 20479691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
    Benedetti G; Latini L; Galetta D; Colucci G; Crinò L
    J Thorac Oncol; 2009 Jul; 4(7):936-7. PubMed ID: 19550250
    [No Abstract]   [Full Text] [Related]  

  • 19. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
    Faehling M; Eckert R; Kamp T; Kuom S; Griese U; Sträter J; Ott G; Spengler W
    Lung Cancer; 2013 Jun; 80(3):306-12. PubMed ID: 23489557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
    Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
    J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.